About Arkuda Therapeutics
Arkuda Therapeutics is a Healthcare company based in Watertown (United States) founded in 2018 by Duane Burnett and Gerhard Koenig. Therapeutic agents for neurological disorders are developed. Arkuda Therapeutics has raised $108 million across 2 funding rounds from investors including Lilly, Pfizer and Citadel. The company has 28 employees. Its chief executive, as recorded, is Gerhard Koenig. Arkuda Therapeutics offers products and services including Neurodegenerative Therapies. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is ARKUDA THERAPEUTICS INC. Its competitors include Biogen, Denali Therapeutics and Intra-Cellular Therapies; 3 of its 3 listed competitors have raised funding.
Company details
Arkuda Therapeutics was established in 2018 in Watertown, United States, within the biotechnology sector. Research and development efforts are directed toward novel drugs that target genetic and molecular factors in neurodegenerative disorders. Therapeutic solutions for neurological diseases are pursued through innovative approaches. Operations are led by co-founders Duane Burnett and Gerhard Koenig, who serves as CEO.
- Headquarters Watertown, United States
- Employees 28
- Founders Duane Burnett, Gerhard Koenig
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website arkudatx.com
- Social LinkedIn X
- Legal Name Arkuda Therapeutics Inc
- Total Equity Funding$108M (USD)
in 2 rounds
- Latest Funding Round$64M (USD), Series B
Feb 2022
- InvestorsLilly
& 7 more
- Employee Count28
Products & Services of Arkuda Therapeutics
Arkuda Therapeutics offers a comprehensive portfolio of products and services, including Neurodegenerative Therapies.
Therapies designed to alter progression of neurodegenerative diseases.
Funding Insights of Arkuda Therapeutics
Arkuda Therapeutics has successfully raised a total of $108M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $64 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108M
- Total Rounds 2
- Last Round Series B — $64M
- First Round $44M
(Nov 2019)
- Investors Count 8
All 2 funding rounds of Arkuda Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $64M | Series B | – | Cormorant Asset Management, Pivotal bioVenture Partners | |
| Nov 2019 | $44M | Series A | – | Pfizer, Atlas Venture |
8 investors in total: 8 institutional.
Investors in Arkuda Therapeutics
Arkuda Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Pfizer and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare startups are funded by this venture capital firm. | Ponte Vedra, United States | |||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Investment advisory services are provided to financial clients. | 1986 | teklacap.com | Boston, United States | |
A global healthcare investment firm supporting therapeutic-focused companies. | 2017 | pivotalbiovp.com | San Francisco, United States |
Investor details for Arkuda Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arkuda Therapeutics
12 people are tracked at Arkuda Therapeutics (6 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 28.
| Name | Role | Group |
|---|---|---|
Duane Burnett | Co-Founder | Leadership |
Gerhard Koenig | Co-Founder & CEO | Leadership |
Irena Webster | VP, Program Strategy & Dev Ops | Leadership |
Mike Esposito | VP, Finance | Leadership |
Jean-François Blain | VP, Neurobiology | Leadership |
Jim Lanter | VP, Medicinal Chemistry | Leadership |
Pascale Witz | Director | Board & advisors |
Bruce Booth | Chairman | Board & advisors |
Christopher O’Donnell | Director | Board & advisors |
Raymond J. Kelleher | Director | Board & advisors |
Gennifer Greenberg | Senior Research Associate | Team |
Denise Peters | Accounting Controller | Team |
Complete people profiles for Arkuda Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Arkuda Therapeutics
3 dated milestones of Arkuda Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Arkuda Therapeutics is founded.
- Funding First funding round of $44.0M.
- Funding Latest funding round, Series B, of $64.0M.
Competitors of Arkuda Therapeutics
Arkuda Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, Denali Therapeutics and Intra-Cellular Therapies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases |
Detailed competitors of Arkuda Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arkuda Therapeutics
Websites that share an audience with Arkuda Therapeutics (arkudatx.com).
Websites whose visitors overlap most with Arkuda Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sherlock.bio | 100% | 2.8K | #4,929,420 | View details | |
liliumdiagnostics.com | liliumdiagnostics.com | 98% | #7,166,163 | – | |
| aldatubio.com | 96% | 1.5K | #12,763,889 | View details | |
| dayzerodiagnostics.com | 96% | 1.4K | #5,790,285 | View details | |
| landmarkbio.com | 95% | 1.9K | #8,466,954 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Arkuda Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Arkuda Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arkuda Therapeutics
Complete news archive for Arkuda Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arkuda Therapeutics
Arkuda Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Arkuda Therapeutics is headquartered in Watertown, United States.
Gerhard Koenig is the CEO of Arkuda Therapeutics, as recorded in our data. They have also founded this company.
Arkuda Therapeutics is a funded company, having raised a total of $108M across 2 funding rounds to date. The company's 1st funding round was a Series A of $44M, raised on Nov 2019.
Arkuda Therapeutics has 28 employees.
Arkuda Therapeutics was established in 2018 in Watertown, United States, within the biotechnology sector. Research and development efforts are directed toward novel drugs that target genetic and molecular factors in neurodegenerative disorders. Therapeutic solutions for neurological diseases are pursued through innovative approaches. Operations are led by co-founders Duane Burnett and Gerhard Koenig, who serves as CEO.
Arkuda Therapeutics's top competitors include Intra-Cellular Therapies, Denali Therapeutics and Biogen.
Arkuda Therapeutics offers Neurodegenerative Therapies.
Arkuda Therapeutics has 8 investors. Key investors include Lilly, Pfizer, Citadel, Atlas Venture, and Tekla Capital Management.
Arkuda Therapeutics operates through Arkuda Therapeutics Inc.